Article
Hematology
Eric Bruckert, Sonia Caprio, Albert Wiegman, Min-Ji Charng, Cezar A. Zarate-Morales, Marie T. Baccara-Dinet, Garen Manvelian, Anne Ourliac, Michel Scemama, Stephen R. Daniels
Summary: This study examined the efficacy and safety of the PCSK9 inhibitor, alirocumab, in pediatric patients with homozygous familial hypercholesterolemia. The results showed that alirocumab effectively reduced LDL-C levels and achieved good treatment outcomes in some patients. This study is of great importance for improving the treatment of homozygous familial hypercholesterolemia.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2022)
Article
Health Care Sciences & Services
Ju Hwan Kim, Chin-Yao Shen, Philip Chun-Ming Au, Yeon-Hee Baek, Ching-Lung Cheung, Wei-Pang Chung, Nora Joelle Kleinman, Tai Chung Lam, Tzu-Chi Liao, Tzu-Chieh Lin, Ju-Young Shin, Chor-Wing Sing, Ian Chi Kei Wong, Edward Chia-Cheng Lai
Summary: This study describes the epidemiology, clinical characteristics, and utilization patterns of bone-targeting agents (BTAs) in patients with bone metastases from breast, prostate, and lung cancer. The findings show that the utilization rate of BTAs remains low in recent years and varies between different regions and tumor types.
BMJ SUPPORTIVE & PALLIATIVE CARE
(2022)
Article
Medicine, General & Internal
Nandor Szegedi, Evgeniy Kroptkin, Vassil Traykoc, Ayan Abdrakhmanov, Faizel Lorgat, Oleg Sapelnikov, Stefanie Simons, Mohammad Amin
Summary: This study aims to evaluate the radiation exposure during catheter ablation of supraventricular tachycardia using the EnSite Precision 3D mapping system, and assess the safety and efficacy of this method. The study will be conducted at multiple sites in 13 countries, with a follow-up period of 6 months for 700 patients. The results will be disseminated through publication and conference presentations.
Article
Medicine, General & Internal
Ben Colagiuri, Louise Sharpe, Zahava Ambarchi, Nick Glozier, Delwyn Bartlett, Daniel S. J. Costa, Amelia Scott
Summary: Insomnia is a common sleep disorder that can have significant personal and societal impacts. This study aims to compare the efficacy of open-label placebo (OLP), conventional placebo (CP), and no treatment for insomnia. The results will provide insight into the effects and predictors of uptake and responses to OLP and CP for insomnia.
Article
Psychiatry
Amke Mueller, Stefan Konigorski, Carina Meissner, Tahmine Fadai, Claire V. Warren, Irina Falkenberg, Tilo Kircher, Yvonne Nestoriuc
Summary: The study aims to assess the effectiveness of open-label placebo (OLP) treatment in reducing antidepressant discontinuation symptoms through a series of N-of-1 trials. The trials will be conducted on patients with fully remitted major depressive disorder, and the primary outcome will be self-reported discontinuation symptoms and expectations, as well as mood.
Article
Oncology
Melody A. Cobleigh, Charles L. Vogel, Debu Tripathy, Nicholas J. Robert, Susy Scholl, Louis Fehrenbacher, Janet M. Wolter, Virginia Paton, Steven Shak, Gracie Lieberman, Dennis J. Slamon
Summary: Recombinant humanized anti-HER2 monoclonal antibody as a single agent shows durable objective responses and good tolerability in women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Sae Jeong Yang, Kyung Wan Min, Sandeep Kumar Gupta, Joong Yeol Park, Vyankatesh K. Shivane, Pankaj Kumar Agarwal, Doo Man Kim, Yong Esong Kim, Sei Hyun Baik
Summary: The extension study evaluated the long-term efficacy and safety of gemigliptin 50 mg in patients with type 2 diabetes mellitus. Results showed a significant reduction in HbA1c levels and overall safety and tolerability up to 52 weeks, highlighting the positive effects of gemigliptin in managing T2DM.
DIABETES & METABOLISM JOURNAL
(2021)
Article
Oncology
Yoon-Koo Kang, Suzanne George, Robin L. Jones, Piotr Rutkowski, Lin Shen, Olivier Mir, Shreyaskumar Patel, Yongjian Zhou, Margaret von Mehren, Peter Hohenberger, Victor Villalobos, Mehdi Brahmi, William D. Tap, Jonathan Trent, Maria A. Pantaleo, Patrick Schoeffski, Kevin He, Paggy Hew, Kate Newberry, Maria Roche, Michael C. Heinrich, Sebastian Bauer
Summary: Avapritinib, a potent inhibitor of KIT and PDGFRA mutant kinases, showed clinical activity in GISTs with specific mutations. The VOYAGER study comparing avapritinib and regorafenib in advanced GIST patients did not find a significant difference in median progression-free survival, but showed similar overall survival and safety profiles between the two treatments.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Xi Ding, Wei-Jing Zhang, Rui You, Xiong Zou, Zhi-Qiang Wang, Yan-Feng Ouyang, Lan Peng, You-Ping Liu, Chong-Yang Duan, Qi Yang, Chao Lin, Yu-Long Xie, Si-Yuan Chen, Yong-Long Liu, Chen-Mei Gu, Ruo-Qi Xie, Pei-Yu Huang, Ming-Huang Hong, Yi-Jun Hua, Ming-Yuan Chen
Summary: This study investigated the activity and safety of combining immune checkpoint inhibitors and antiangiogenic therapy for recurrent/metastatic nasopharyngeal carcinoma. The results showed promising antitumor activity with camrelizumab plus apatinib in refractory patients, but there were also treatment-related adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Liam S. Acheson, Nadine Ezard, Nicholas Lintzeris, Adrian Dunlop, Jonathan Brett, Craig Rodgers, Anthony Gill, Michael Christmass, Rebecca McKetin, Michael Farrell, Steve Shoptaw, Krista J. Siefried
Summary: This is the first study to assess lisdexamfetamine for the treatment of acute MA withdrawal. If safe and feasible results will go to informing the development of multi-centre randomised controlled trials to determine the efficacy of the intervention.
Article
Clinical Neurology
Ilona Merikanto, Laura Kortesoja, Christian Benedict, Frances Chung, Jonathan Cedernaes, Colin A. Espie, Charles M. Morin, Yves Dauvilliers, Markku Partinen, Luigi De Gennaro, Yun Kwok Wing, Ngan Yin Chan, Yuichi Inoue, Kentaro Matsui, Brigitte Holzinger, Giuseppe Plazzi, Sergio Arthuro Mota-Rolim, Damien Leger, Thomas Penzel, Bjorn Bjorvatn
Summary: During the COVID-19 pandemic, evening-types experienced poorer mental health, well-being, and quality of life compared to other circadian types. They also reported delayed sleep-wake schedules, increased sleep duration, and more severe sleep problems. Meanwhile, morning-types were less vulnerable to sleep changes and experienced protection from most sleep problems.
Article
Urology & Nephrology
Andrea K. Viecelli, Armando Teixeira-Pinto, Andrea Valks, Richard Baer, Roy Cherian, Pietro E. Cippa, Jonathan C. Craig, Ranil DeSilva, Allison Jaure, David W. Johnson, Charani Kiriwandeniya, Pascal Kopperschmidt, Wen-J Liu, Timmy Lee, Charmaine Lok, Krishan Madhan, Alistair R. Mallard, Veronica Oliver, Kevan R. Polkinghorne, Rob R. Quinn, Donna Reidlinger, Matthew Roberts, Benedicte Sautenet, Lai Seong Hooi, Rob Smith, Maarten Snoeijs, Jan Tordoir, Tushar J. Vachharajani, Raymond Vanholder, Liza A. Vergara, Martin Wilkie, Bing Yang, Theodore H. Yuo, Li Zou, Carmel M. Hawley
Summary: This study aims to assess the accuracy and feasibility of measuring the core outcome of vascular access function. This measurement is crucial for obtaining reliable and relevant evidence to guide patient-centered hemodialysis care in both research and practice.
Article
Medicine, Research & Experimental
Anouk E. Hiensch, Evelyn M. Monninkhof, Martina E. Schmidt, Eva M. Zopf, Kate A. Bolam, Neil K. Aaronson, Jon Belloso, Wilhelm Bloch, Dorothea Clauss, Johanna Depenbusch, Milena Lachowicz, Mireia Pelaez, Helene Rundqvist, Elzbieta Senkus, Martijn M. Stuiver, Mark Trevaskis, Ander Urruticoechea, Friederike Rosenberger, Elsken van der Wall, G. Ardine de Wit, Philipp Zimmer, Yvonne Wengstrom, Karen Steindorf, Anne M. May
Summary: This study aims to evaluate the effects of a 9-month structured and individualized exercise intervention on quality of life, fatigue, and other side effects in patients with metastatic breast cancer. If proven effective, exercise should be offered as part of standard care for these patients.
Article
Immunology
Hyejean Cho, Yongjun Ahn, Taehwan Oh, Jeongmin Suh, Chanhee Chae
Summary: The objective of this study was to evaluate the clinical, immunological, microbiological, and pathological effects of a trivalent vaccine administered by two different needle-free injection devices compared to conventional needle-syringe injection. The results showed that the trivalent vaccine administered by the needle-free devices was as effective as the conventional injection method in reducing PCV2d and M. hyopneumoniae infections.
Article
Oncology
Francesca Salvianti, Stefania Gelmini, Irene Mancini, Mario Pazzagli, Serena Pillozzi, Elisa Giommoni, Marco Brugia, Francesco Di Costanzo, Francesca Galardi, Francesca De Luca, Francesca Castiglione, Luca Messerini, Pamela Pinzani, Lorenzo Antonuzzo
Summary: Liquid biopsy, including cfDNA and CTCs, shows prognostic value in KRAS mutated mCRC. CTCs are a negative prognostic marker at baseline, while cfDNA is easily accessible for monitoring tumor mutations over time. In longitudinal monitoring, these two markers complement each other in assessing disease progression.
BRITISH JOURNAL OF CANCER
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Erwin Woff, Lisa Salvatore, Federica Marmorino, Dario Genovesi, Gabriela Critchi, Thomas Guiot, Lieveke Ameye, Francesco Sclafani, Alain Hendlisz, Patrick Flamen
Summary: This study validates the prognostic value of F-18-FDG PET/CT-based biomarkers in mCRC, with baseline whole-body metabolically active tumor volume and early metabolic response being identified as strong independent prognostic parameters for overall and progression-free survival. Combining these biomarkers improves risk stratification for mCRC patients, regardless of treatment received.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Letter
Oncology
Rita Saude Conde, Giacomo Bregni, Everardo Saad, Alain Hendlisz, Francesco Sclafani
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Heinz-Josef Lenz, Eric Van Cutsem, Maria Luisa Limon, Ka Yeung Mark Wong, Alain Hendlisz, Massimo Aglietta, Pilar Garcia-Alfonso, Bart Neyns, Gabriele Luppi, Dana B. Cardin, Tomislav Dragovich, Usman Shah, Sandzhar Abdullaev, Joseph Gricar, Jean-Marie Ledeine, Michael James Overman, Sara Lonardi
Summary: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
P. J. Ross, H. S. Wasan, D. Croagh, M. Nikfarjam, N. Nguyen, M. Aghmesheh, A. M. Nagrial, D. Bartholomeusz, A. Hendlisz, T. Ajithkumar, C. Iwuji, N. E. Wilson, D. M. Turner, D. C. James, E. Young, M. T. Harris
Summary: This study suggests that combining P-32 microparticles with standard-of-care chemotherapy may have clinically relevant benefits for patients with unresectable locally advanced pancreatic cancer. The treatment has an acceptable safety profile and results in improved local disease control and overall survival.
Article
Oncology
Ali Bohlok, Lisa Inchiostro, Valerio Lucidi, Sophie Vankerckhove, Alain Hendlisz, Jean Luc Van Laethem, Ligia Craciun, Pieter Demetter, Denis Larsimont, Luc Dirix, Peter Vermeulen, Vincent Donckier
Summary: This study investigated the interaction between histological growth pattern (HGP) and surgical margin status in influencing the prognosis of patients undergoing surgery for colorectal liver metastases (CRLMs). The results showed that non-desmoplastic HGP (non-DHGP) was the only predictive factor for R1 margin, and non-DHGP was associated with worse prognosis. Surgical margin status did not have prognostic impact in patients with non-DHGP.
Meeting Abstract
Hematology
Hany Elmariah, Jongphil Kim, Kayla M. Reid, Christopher Cubitt, Andrew Kuykendall, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman, Onyee Chan, Kendra Sweet, Albert J. Ribickas, Rawan Faramand, Asmita Mishra, Farhad Khimani, Lia Perez, Debra Kessler, Stephanie Dormesy, Joseph Pidala, Claudio Anasetti, Ephraim J. Fuchs, Michael D. Jain, Frederick L. Locke, Marco L. Davila, Nelli Bejanyan, Amy E. DeZern
Meeting Abstract
Hematology
Rawan Faramand, Michael D. Jain, Biwei Cao, Xuefeng Wang, Kayla M. Reid, Sae Bom Lee, Salvatore A. Corallo, Meghan A. Menges, Melanie Hidalgo-Vargas, Christina A. Bachmeier, Julio C. Chavez, Bijal D. Shah, Javier Pinilla Ibarz, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Kelly Speth, Qinghua Song, Mike Mattie, Frederick L. Locke, Marco L. Davila
Article
Oncology
Justin C. Boucher, Bin Yu, Gongbo Li, Bishwas Shrestha, David Sallman, Ana Marie Landin, Cheryl Cox, Kumar Karyampudi, Claudio Anasetti, Marco L. Davila, Nelli Bejanyan
Summary: Higher gamma delta T cell counts in patients with malignancies are associated with better survival. Promising results are reported on the treatment of various malignancies with in vivo expansion of autologous gamma delta T cells using zoledronic acid (zol) and interleukin-2 (IL-2). In this study, we demonstrated that a combination of zol and IL-2, along with a novel genetically engineered aAPC, effectively expanded allogeneic donor-derived gamma delta T cells in large quantities for potential clinical use.
JOURNAL OF IMMUNOTHERAPY
(2023)
Article
Biochemistry & Molecular Biology
Christoph K. Stein-Thoeringer, Neeraj Y. Saini, Eli Zamir, Viktoria Blumenberg, Maria-Luisa Schubert, Uria Mor, Matthias A. Fante, Sabine Schmidt, Eiko Hayase, Tomo Hayase, Roman Rohrbach, Chia-Chi Chang, Lauren McDaniel, Ivonne Flores, Rogier Gaiser, Matthias Edinger, Daniel Wolff, Martin Heidenreich, Paolo Strati, Ranjit Nair, Dai Chihara, Luis E. Fayad, Sairah Ahmed, Swaminathan P. Iyer, Raphael E. Steiner, Preetesh Jain, Loretta J. Nastoupil, Jason Westin, Reetakshi Arora, Michael L. Wang, Joel Turner, Meghan Menges, Melanie Hidalgo-Vargas, Kayla Reid, Peter Dreger, Anita Schmitt, Carsten Mueller-Tidow, Frederick L. Locke, Marco L. Davila, Richard E. Champlin, Christopher R. Flowers, Elizabeth J. Shpall, Hendrik Poeck, Sattva S. Neelapu, Michael Schmitt, Marion Subklewe, Michael D. Jain, Robert R. Jenq, Eran Elinav
Summary: Evidence suggests that the gut microbiome may influence the effectiveness of cancer immunotherapy. In a cohort of B cell lymphoma patients from Germany and the United States, it was found that the use of broad-spectrum antibiotics prior to CAR-T cell therapy was associated with negative outcomes. Additionally, certain microbiome features were found to be correlated with the survival and progression of lymphoma in these patients.
Article
Hematology
David A. Sallman, Tessa Kerre, Violaine Havelange, Xavier Poire, Philippe Lewalle, Eunice S. Wang, Jason B. Brayer, Marco L. Davila, Ine Moors, Jean-Pascal Machiels, Ahmad Awada, Erik M. Alcantar-Orozco, Rossitza Borissova, Nathalie Braun, Marie-Sophie Dheur, David E. Gilham, Caroline Lonez, Frederic F. Lehmann, Anne Flament
Summary: CYAD-01, an autologous CAR T-cell product, targeting NKG2D ligands, showed anti-leukaemic activity and was well tolerated without preconditioning. Phase 1 data support the proof-of-concept and further clinical studies are warranted to improve anti-tumour activity.
LANCET HAEMATOLOGY
(2023)
Article
Hematology
Ning Dong, Lucia Rubio Lopes-Garcia, David Vinal, Christina Bachmeier, Bijal D. Shah, Taiga Nishihori, Farhad Khimani, Marco L. Davila, Aleksandr Lazaryan, Javier Pinilla-Ibarz, Frederick L. Locke, Michael D. Jain, Julio C. Chavez
Summary: This study evaluated the outcomes of axicel and tisacel CAR-T therapy in patients with transformed nonfollicular lymphomas (tNFL), including those who received concomitant ibrutinib treatment. The results showed that CD19 CAR-T therapy had good efficacy in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (tCLL/SLL) and transformed marginal zone lymphoma (tMZL) patients, while tNFL patients were more prone to immune effector cell-associated neurologic syndrome (ICANS) compared to DLBCL/tFL patients. Summary: CD19 CAR-T therapy has favorable efficacy in tCLL/SLL and tMZL patients, but careful monitoring is needed in tNFL patients. Overall, this study provides valuable insights into the use of CAR-T therapy in different types of lymphomas.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Anthony C. Wood, Ariel Perez Perez, Brian Arciola, Kedar Patel, Grace Johnson, Elizabeth DiMaggio, Christina A. Bachmeier, Kayla Reid, Salvatore Carallo, Melanie H. Vargas, Rawan Faramand, Julio C. Chavez, Bijal Shah, Sameh Gaballa, Farhad Khimani, Hany Elmariah, Taiga Nishihori, Aleksandr Lazaryan, Ciara Freeman, Marco L. Davila, Frederick L. Locke, Rahul Mhaskar, Claude Bassil, Michael D. Jain
Summary: This study evaluated the outcomes of renal impairment patients receiving CAR T cell therapy for DLBCL. Results showed that renal impairment did not affect renal or survival outcomes, but patients with acute kidney injury had worse clinical outcomes.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Meeting Abstract
Cardiac & Cardiovascular Systems
Dae H. Lee, Michael Jain, Rawan G. Faramand, Kayla Reid, Sae Bom Lee, Salvatore Corallo, Melanie Hidalgo-Vargas, Abhishek Kumar, Sanjay Chandrasekhar, Julio Chavez, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Frederick Locke, Guilherme Oliveira, Mohammed Alomar, Marco L. Davila
Article
Oncology
Neeraj Y. Saini, David M. Swoboda, Uri Greenbaum, Junsheng Ma, Romil D. Patel, Kartik Devashish, Kaberi Das, Mark R. Tanner, Paolo Strati, Ranjit Nair, Luis Fayad, Sairah Ahmed, Hun Ju Lee, Swaminathan P. Iyer, Raphael Steiner, Nitin Jain, Loretta Nastoupil, Sanam Loghavi, Guilin Tang, Roland L. Bassett, Preetesh Jain, Michael Wang, Jason R. Westin, Michael R. Green, David A. Sallman, Eric Padron, Marco L. Davila, Frederick L. Locke, Richard E. Champlin, Guillermo Garcia-Manero, Elizabeth J. Shpall, Partow Kebriaei, Christopher R. Flowers, Michael D. Jain, Feng Wang, Andrew P. Futreal, Nancy Gillis, Sattva S. Neelapu, Koichi Takahashi
Summary: This study reveals that clonal hematopoiesis mutations, particularly those associated with inflammation (DNMT3A, TET2, and ASXL1), are associated with severe-grade neurotoxicities in lymphoma patients receiving anti-CD19 CAR T-cell therapy. Furthermore, the incidence of therapy-related myeloid neoplasms after CAR T-cell therapy is higher in clonal hematopoiesis-positive patients.
BLOOD CANCER DISCOVERY
(2022)
Meeting Abstract
Cardiac & Cardiovascular Systems
Dae Hyun Lee, Sanjay Amrith Chandrasekhar, Michael Jain, Doris Hansen, Ciara Freeman, Melissa Alsina, Rachid Baz, Omar Castaneda Puglianini, Hien Liu, Brandon Blue, Marco L. Davila, Rawan Faramand, Abhishek Kumar, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Frederick Locke, Guilherme Henrique Oliveira, Mohammed Alomar
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)